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Abstract
Rare, inactivating mutations in the BRCA1 gene appear to play a limited role in prostate cancer. To
our knowledge, however, no study has comprehensively assessed the role of other BRCA1
sequence variations, e.g., missense mutations, in prostate cancer. In a study of 817 men with and
without prostate cancer from 323 familial and early-onset prostate cancer families, we used
family-based association tests and conditional logistic regression to investigate the association
between prostate cancer and single nucleotide polymorphisms (SNPs) tagging common haplotype
variation in a 200 kb-region surrounding (and including) the BRCA1 gene. We also used the
Genotype-IBD Sharing Test (GIST) to determine whether our most strongly associated SNP could
account for prostate cancer linkage to chromosome 17q21 in a sample of 154 families from our
previous genome-wide linkage study. The strongest evidence for prostate cancer association was
for a glutamine-to-arginine substitution at codon 356 (Gln356Arg) in exon 11 of the BRCA1 gene.
The minor (Arg) allele was preferentially transmitted to affected men (p=0.005 for a dominant
model), with an estimated odds ratio of 2.25 (95% confidence interval = 1.21 to 4.20). Notably,
BRCA1 Gln356Arg is not in strong linkage disequilibrium with other BRCA1 coding SNPs or any
known HapMap SNP on chromosome 17. In addition, GIST results suggest that Gln356Arg
accounts (in part) for our prior evidence of prostate cancer linkage to chromosome 17q21
(p=0.022). Thus, we have identified a common, non-synonymous substitution in the BRCA1 gene
that is associated with and linked to prostate cancer.
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Introduction
Germ-line, loss-of-function mutations in the BRCA1 gene on chromosome 17q21
substantially increase the lifetime risk of developing breast and ovarian cancer. BRCA1
mutations may also confer an increased risk of other cancers. Specifically, some studies
(although not all(1;2)) have suggested an increased risk of prostate cancer among male
carriers of deleterious BRCA1 mutations in breast and ovarian cancer families(3–5). For
example, Ford et al.(3) reported a significant excess of prostate cancer cases in breast and
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ovarian families with evidence of linkage to BRCA1. Similarly, based on families with a
history of breast and/or ovarian cancer and with at least one individual known to carry a
pathogenic mutation in the BRCA1 gene, Thompson et al.(5) reported an approximately two-
fold increased relative risk of prostate cancer in BRCA1 mutation carriers compared to non-
carriers, although the effect was restricted to men who were young at their time of diagnosis
(less than 65 years of age).
In a previous genome-wide scan (GWS) based on 175 families from the University of
Michigan Prostate Cancer Genetics Project (PCGP), our strongest signal for prostate cancer
linkage was on chromosome 17q21 (maximum logarithm of odds (LOD) scores (MLSs) of
2.36 in all families and 3.28 in the subset of families with 4 or more affected men)(6).
Similarly, in a subsequent, combined genome-wide linkage analyses of 1,233 families from
ten(7) independent studies of hereditary prostate cancer (including the 175 families from our
PCGP study) chromosome 17q21 was among the top five regions with evidence of prostate
cancer linkage. Notably, the strongest linkage signal for hereditary prostate cancer in the
PCGP study is within 5 cM of the BRCA1 gene (on chromosome 17q21), suggesting the
presence of a susceptibility locus near, if not within, the BRCA1 gene region.
Since the majority of identified BRCA1 mutations are nonsense or frameshift mutations that
result in a truncated protein product, most studies to date have focused exclusively on the
relationship between obvious loss-of-function mutations (e.g., protein truncating mutations)
in BRCA1 and prostate cancer. Screening of hereditary prostate cancer families (including
our own(8)), however, suggests that these rare, highly penetrant mutations are unlikely to
account for a sizeable fraction of hereditary prostate cancer cases(9–11). Still, to our
knowledge, no large, comprehensive study has definitively assessed the role of other
sequence variations in BRCA1, e.g., missense mutations, as a contributor to prostate cancer
risk. To more comprehensively survey genetic variation in the BRCA1 gene in relation to
prostate cancer risk, we genotyped a set of SNPs tagging haplotype variation in a 200 kb-
region surrounding (and including) the BRCA1 gene and assessed their association with




The PCGP is a large, ongoing family-based study designed to identify genes predisposing to
inherited forms of prostate cancer. Enrollment into the PCGP is restricted to (1) families
with two or more living members with prostate cancer in a first- or second-degree
relationship or (2) men diagnosed with prostate cancer at ≤55 years of age without a family
history of the disease. All participants are asked to provide a blood sample, extended family
history information, and access to medical records. For the present investigation, we
identified 338 families in which we had DNA from at least one pair of brothers discordant
for prostate cancer. These discordant sibling pairs (DSPs) were selected from a single
generation to mitigate potential cohort effects. We also preferentially enrolled the oldest
available unaffected brother from each family to maximize the probability that unaffected
men were truly unaffected and not simply unaffected by virtue of being younger than their
affected brother(s). Additional male siblings as well as multiple sibships from the same
family were included if DNA was available.
The majority of the PCGP families were recruited directly from the University of Michigan
Comprehensive Cancer Center. Other sources included direct patient or physician referrals.
Diagnosis of prostate cancer was confirmed by review of pathology reports or medical
records, and age at diagnosis was calculated from the date of the first biopsy positive for
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prostate cancer. Cases were classified as clinically aggressive if they met at least one of the
following criteria: (1) pathologic Gleason sum > 7, (2) pathologic stage T3b (pT3b) tumor
(indicating seminal vesicle involvement) or pT4 or N1 (positive regional lymph nodes), (3)
pathologic Gleason sum of 7 and a positive margin, or (4) pre-operative serum prostate-
specific antigen (PSA) value >15 ng/ml, or a biopsy Gleason score > 7, or a serum PSA
level > 10 ng/ml and a biopsy Gleason score > 6. Based on data from D’Amico et al.(13),
these criteria were developed by the Southwest Oncology Group (protocol 9921) to identify
men at intermediate to high risk of clinical recurrence after primary therapy. Disease status
of the unaffected brothers was confirmed through serum PSA testing whenever possible.
The majority of the families were non-Hispanic white, although 13 African American and 2
Asian families were also recruited. All of the following results, however, were restricted to
the sample of 323 non-Hispanic white families. This decision was supported by an analysis
of the HapMap(14) samples, which revealed substantial allele frequency differences and
dissimilar linkage disequilibrium (LD) patterns in the BRCA1 gene region between African,
Asian, and European samples. The Institutional Review Board at the University of Michigan
Medical School approved all aspects of the protocol, and all participants gave written
informed consent, including permission to release their medical records.
Genotyping Assays
Genomic DNA was isolated from whole blood using the Puregene kit (Gentra Systems Inc.,
Minneapolis, MN). A validated SNP, rs7223952, located downstream of BRCA1, was
selected and genotyped from the Assays-On-Demand catalog (Applied Biosystems, Foster
City, CA). After this SNP displayed significant association with prostate cancer, we used the
haplotype tagging strategy described below to select and genotype six additional SNPs:
rs2271539 in intron 2 of the RPL27 gene; rs691144 in intron 1 of the IFI35 gene; and
rs1799966, rs3737559, rs1799950, and rs799923 in exon 17, intron 13, exon 11, and intron
6, respectively, of the BRCA1 gene. We genotyped all 7 SNPs with the TaqMan allelic
discrimination assay, and we used the ABI PRISM 7900HT Sequence Detection System
(Applied Biosystems) to distinguish SNP alleles as previously described(12). Assay details
are available from the authors on request. On average, we achieved a genotyping call rate of
98.94%, with call rates >97.46% for each SNP. We sequenced SNPs that were undetermined
by the assay for a final genotyping call rate of 100%. A subset of samples were also
duplicated and verified by either TaqMan SNP genotyping or direct sequencing. We
observed 3 discrepancies among 363 duplicate genotype pairs by TaqMan SNP genotyping
and 1 discrepancy among 166 duplicate genotype pairs by direct sequencing, yielding
genotyping reproducibility rates of 99.2% and 99.4%, respectively.
Haplotype Tagging Strategy
Based on the HapMap(14) data (February 2005 release), a total of 71 SNPs mapped to the
200 kb interval around our originally associated SNP, rs7223952, and 41 of these SNPs
were present in at least one of 60 unrelated individuals from a U.S. Utah population with
northern and western European ancestry (abbreviated CEU). Using these data, we applied
the dynamic programming algorithm proposed by Zhang et al.(15) and implemented in
HapBlock(16) (version 3.0) to partition this 200 kb region into blocks and select a
maximally informative set of SNPs. Specifically, we defined common haplotypes as those
having frequency >3% (i.e., haplotypes inferred to be present at least 4 times among 120
chromosomes), and we defined a consecutive set of SNPs as a block if common haplotypes
accounted for at least 80% of all predicted haplotypes. We then determined haplotype-tag
SNPs (htSNPs) as the minimum set of SNPs that distinguished all common haplotypes
inferred within each block. Based on these criteria, the 41 SNPs clustered into two, non-
overlapping blocks of limited haplotype diversity, and six htSNPs (rs2271539 and rs691144
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in the first block and rs1799966, rs3737559, rs1799950, and rs799923 in the second block)
distinguished 94% and 96% of all haplotypes inferred within the first and second blocks,
respectively (Figure 1). SNP rs7223952, which is not present in the HapMap database, is
located in the second block.
Data Analysis Methods
The observed genotype distributions were tested for departures from Hardy-Weinberg
equilibrium in a subset of unrelated men by selecting the oldest unaffected man from each
family. Two-SNP haplotype frequencies were estimated using the expectation-maximization
algorithm and were used to calculate the LD measure R2 between each pair of SNPs. For
comparison, we also estimated minor allele frequencies, two-SNP haplotypes, and LD in
unrelated individuals from the HapMap CEU sample (n=60).
We used conditional logistic regression with family as the stratification variable and a robust
variance estimate that incorporates familial correlations due to potential linkage(17) to
estimate odds ratios (OR’s) and 95% confidence intervals (CI’s) for the association between
genotypes and prostate cancer. In parallel, we used the Family-Based Association Test
(FBAT) program (version 1.5.5) to test for association between genotypes and prostate
cancer. FBATs are a class of generalized score statistics that utilize within- and between-
family marker-inheritance patterns to test for association (18;19). Given our prior evidence
of prostate cancer linkage to chromosome 17q21, we employed the empirical variance
function in FBAT, which is a valid test of the null hypothesis of no association in the
presence of linkage. To maximize power, we analyzed the combined sample of affected and
unaffected men using the offset option. We also carried out affecteds-only analyses to allow
for the possibility of misclassification of unaffected men (e.g., via reduced penetrance). Both
conditional logistic regression analyses and FBATs were carried out assuming additive,
dominant, and recessive genetic models. For conditional logistic regression and affecteds-
only FBATs, we also examined a general (2 degrees of freedom) genotype model.
Predetermined stratified analyses were also performed to explore the relationship between
genotypes and prostate cancer, stratifying on clinically aggressive prostate cancer, age at
diagnosis (<50 years), or number of confirmed cases of prostate cancer within a family (≥3).
To account for the number of correlated tests performed (i.e., 3 genetic models for each of 7
SNPs), we performed permutation tests to assess the overall significance of our primary
FBAT results in the combined sample of affected and unaffected men. Specifically, we
created 1,000 permuted samples by randomly permuting the affection status labels of
genotyped men within each sibship (i.e., leaving intact the vector of correlated SNPs). For
each permuted sample, we performed the FBATs described above assuming additive,
dominant, and recessive genetic models. We then compared the number of significant
associations in the permuted samples with the number of significant associations originally
found. The overall p-value was computed as the proportion of permuted samples having at
least as many tests with p-values less than or equal to the least significant p-value from the
analyses of the original data.
To assess the association of haplotypes with prostate cancer, we divided each of the htSNPs
by block and examined two- and four-SNP haplotypes corresponding to the first and second
blocks, respectively. We also examined six-SNP haplotypes by combining SNPs from both
blocks. Because our originally associated SNP, rs7223952, was in strong LD (R2=0.94) with
one of the htSNPs, rs1799966, we excluded it from our haplotype-based analyses. All
haplotypes were analyzed using the haplotype FBAT (HBAT) method(20). We jointly tested
all n-SNP haplotypes (where n=2, 4, or 6) for association with prostate cancer (i.e., a global
test). We also tested each individual haplotype for association with prostate cancer,
assuming additive, dominant, and recessive genetic models. As described above for FBAT,
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we used the empirical variance option to account for prostate cancer linkage to this region
and the offset option to weight the contribution of unaffected and affected subjects.
To determine whether our most strongly associated SNP, rs1799950, explained our prior
evidence of prostate cancer linkage to chromosome 17q21, we genotyped it in 154 of the
original 157 GWS families of non-Hispanic white descent(6). These 154 families included
411 affected and 72 unaffected men for whom we had sufficient DNA. We then used the
Genotype-IBD Sharing Test (GIST) proposed by Li et al.(21) and implemented in version
0.3 of their program to determine if the linkage signal was explained by rs1799950. The
GIST tests for a positive correlation between family-specific weights (based on genotypes of
affected family members, e.g., at rs1799950, and the model of interest, e.g., dominant) and
family-based identity-by-descent (IBD) sharing as represented by the non-parametric
linkage (NPL) score. Using the 15 microsatellite markers on chromosome 17 from our
original GWS(6), we re-calculated non-parametric multipoint LOD scores using Merlin(22)
(version 1.0.0) with the ‘pairs’ scoring statistic, the exponential model, and equal weights
for each of the 154 families. To investigate the evidence for linkage in the families without
(with) the risk allele, we re-computed non-parametric multipoint LOD scores in the subset
of families in which no affected men (at least one affected man) carried the risk allele.
All statistical tests were two-sided, and p-values < 0.05 were considered statistically
significant. Conditional logistic regression was conducted using version 8.2 of the SAS
programming language (SAS Institute, Cary, NC). All remaining analyses (except where
noted above) were conducted using the R language (version 2.1.1).
Results
Characteristics of the Families and Men
For this investigation, we identified 323 non-Hispanic white families with at least one
discordant sibling pair (DSP), resulting in a total of 516 DSPs. Of the 323 families, 316
included only the index case and one or more of his brothers. The remaining 7 families
included additional DSPs unrelated to the index case as a brother (e.g., a pair of DSPs
related as first cousins). Approximately 32%, 38%, and 30% of families included one, two,
and three or more men with prostate cancer, respectively. The total sample consisted of 817
men (434 affected and 383 unaffected men). The clinical characteristics of the men with
prostate cancer are shown in Table 1. The median age at diagnosis was 55 years (inter-
quartile range=50–63 years). The median age of unaffected men at their time of consent was
56 years (inter-quartile range=50–63 years). Approximately 76% of unaffected men reported
their most recent PSA testing results and/or had their PSA values confirmed by medical
record review, and ~95% of them reported and/or had a PSA level <4.0 mg/dL or normal. At
the time of consent, unaffected men were significantly older than their affected brothers
were at their time of diagnosis (p<0.0001 for paired t-test of within family means), with a
mean age difference of ~3 years.
Allele Frequencies and Disequilibrium Analyses
Initially, we genotyped SNP rs7223952, which is located ~1.6 kb downstream of the poly-
adenylation site of the BRCA1 gene on chromsome 17q21. Based on the haplotype tagging
strategy described above (see Materials and Methods), we then genotyped six additional
SNPs spanning a 200 kb region around rs7223952. Positions and minor allele frequencies
for all seven SNPs are given in Table 2 for affected and unaffected men. The observed
genotype data were consistent with Hardy-Weinberg equilibrium. The pattern of LD in the
200-kb region surrounding rs7223952 is shown in Figure 1 for the sample of unrelated,
unaffected men. Consistent with our haplotype tagging strategy, 16 of all 21 SNP pairs
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exhibited weak LD (R2<0.2). SNP rs7223952, which was not present in the HapMap
database and therefore did not inform our htSNP selection strategy, was in strong LD with
htSNP rs1799966 (R2=0.94). In general, the LD patterns in Figure 1 were consistent with
those predicted by the HapMap CEU sample (data not shown).
Single SNP and Haplotype-Based Association Analyses
Table 3 summarizes results for all seven SNPs using both conditional logistic regression and
family-based association tests. Conditional logistic regression analyses were based on a
single sib-ship per family (799 affected and unaffected men or 506 DSPs). Initial FBAT
analyses included only affected men (n=434), while the primary, combined analyses
(reported below) included all affected and unaffected men (n=817). We initially identified a
weak association between prostate cancer and SNP rs7223952 downstream of the BRCA1
gene. However, after genotyping an additional 6 htSNPs, our strongest evidence for prostate
cancer association was for SNP rs1799950, which results in a glutamine-to-arginine
substitution at codon 356 (Gln356Arg) in exon 11 of the BRCA1 gene. The minor allele of
rs1799950 was preferentially transmitted to affected men (z = 2.79; p=0.005 for a dominant
model), with an odds ratio of 2.25 (95% CI = 1.21–4.20; p-value=0.011). There was an
insufficient number of Arg/Arg genotypes to evaluate other genetic models for rs1799950.
Another SNP in the BRCA1 gene, rs3737559 in intron 13, also revealed significant evidence
of prostate cancer association (z=−2.37; p=0.018 for a dominant model). This SNP was less
strongly but still significantly associated with prostate cancer under an additive model (data
not shown). In contrast, under an additive (but not dominant) genetic model, the minor allele
at SNP rs799923 in intron 6 of the BRCA1 gene was preferentially transmitted to affected
men (z=2.07; p=0.039), with an odds ratio of 1.39 (95% CI = 0.99,1.95; p=0.056). Each of
these associated SNPs (rs1799950, rs3737559, and rs799923) were in weak LD (R2<0.2)
with each other and with rs7223952 in our sample of unrelated, unaffected men (Figure 1).
We found no evidence of an association between SNPs rs2271539, rs691144, or rs1799966
and prostate cancer. Thus, a total of 3 SNPs exhibited significant prostate cancer association
in 5 FBATs for the combined sample of affected and unaffected men. Among 1,000
permuted samples, only 24 samples had 5 or more FBAT results with a p-value ≤ 0.039 (our
least significant FBAT p-value), indicating that these association results are unlikely to be
due to chance alone (p=0.024).
As described above, analyses were repeated after stratifying on clinically aggressive prostate
cancer, age at diagnosis (<50 years), and number of confirmed cases of prostate cancer
within a family (≥3). After stratification, the minor allele at SNP rs1799950 was
preferentially transmitted to affected men in the subset of families in which affected men
were diagnosed with prostate cancer at <50 years of age (z= 2.89; p=0.004 for a dominant
model), with an odds ratio of 7.51 (95% CI = 0.74–76.23; p=0.082). In the subset of families
with 3 or more confirmed affected men, the minor allele at SNP rs3737559 was
preferentially transmitted to unaffected men (z=−2.49; p=0.013 for a dominant model), with
an odds ratio of 0.23 (95% CI = 0.03,2.14; p=0.200). These stratified results are consistent
with the FBAT results based on all families and are statistically significant despite a
substantial loss of informative families, over half in both cases (12 versus 49 families for
rs1799950 and 20 versus 47 families for rs3737559). Although SNP rs2271539 was not
significantly associated with prostate cancer in the un-stratified analyses, the major allele
was preferentially transmitted to affected men in the subset of families with 3 or more
confirmed affected men (z=−2.53; p=0.012 for a dominant model), with an odds ratio of
0.40 (95% CI = 0.17–0.95; p=0.038). Results for SNPs rs3737559 and rs2271539 were also
statistically significant under an additive model. We found no significant evidence of an
association between SNPs rs691144, rs7223952, rs1799966, or rs799923 and prostate cancer
in any of the stratified analyses.
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Haplotype analysis did not reveal a risk haplotype or set of haplotypes that explained our
prostate cancer associations substantially more than individual SNPs (data not shown).
Further, the only significantly associated haplotype contained the most significantly
associated SNP, rs1799950. For example, the 4-SNP haplotype uniquely defined by the
minor allele at rs1799950 was over-transmitted to affected men (z=2.812; p=0.005 for a
dominant model), consistent with single-SNP results for rs1799950. Similarly, the 6-SNP
haplotype uniquely defined by the minor allele of rs1799950 was also significantly over-
transmitted to affected men under a dominant model (z=2.317; p=0.020 for a dominant
model).
Linkage Analyses
We followed up the most significant SNP, rs1799950, by genotyping it in our 154 non-
Hispanic white GWS families and using the GIST to test whether it explained our original
linkage signal on chromosome 17q21. It should be noted that 74 of these 154 GWS families
overlapped with the 323 families from the current family-based association study (Table 4),
in which we have already established evidence of prostate cancer linkage to rs1799950 (via
FBAT). At least one affected man carrying at least one copy of the minor allele at rs1799950
was present in 25 of the 154 GWS families. Using the GIST, we found evidence for an
association between the presence of the risk (or minor) allele in affected men and increased
IBD allele sharing among brothers affected with prostate cancer (p=0.022 for a dominant
model), suggesting that SNP rs1799950 contributes to our originally reported linkage signal
on chromosome 17q21(6). Notably, evidence of suggestive prostate cancer linkage to
chromosome 17q21 remained after we removed families in which affected men carried one
or more copies of the minor allele at rs1799950 (MLS of 1.45 in 129 non-carrier families
versus 1.93 in all 154 families) (Figure 2). By comparison, we observed a LOD score of
0.85 at rs1799950 in the 25 carrier families.
Discussion
In summary, we found three common SNPs (i.e., minor allele frequency greater than 5%) in
the BRCA1 gene, rs1799950, rs3737559, and rs799923, which are associated with prostate
cancer and are in weak LD with each other. Our strongest evidence for prostate cancer
association was for SNP rs1799950, or equivalently Gln356Arg. We estimate that men
carrying at least one Arg356 allele are approximately twice as likely to develop prostate
cancer as non-carriers. If BRCA1 Gln356Arg is causally related to prostate cancer, we
estimate a population attributable fraction (PAF) of ~13%. This PAF is based on the
frequency of the Arg356 allele in our sample of unaffected men and applies to the
population of early onset, familial prostate cancer. Remarkably, this SNP also contributes, in
part, to our prior evidence of prostate cancer linkage to chromosome 17q21(6). Thus, we
now have evidence of both linkage and association between prostate cancer and common
variation in the BRCA1 gene. Not unexpectedly, our results also suggest that BRCA1
Gln356Arg accounts only partially for prostate cancer linkage to chromosome 17q21,
indicating that there are likely multiple functional variants in this region that influence
prostate cancer susceptibility.
Notably, we found significant evidence of association in several different strata, including
the subset of families in which men were diagnosed with prostate cancer at < 50 years of age
(for SNP rs1799950) and the subset of families with 3 or more affected men (for SNPs
rs2271539 and rs3737559). The former is consistent with the findings of Thompson et al.(5)
that suggested an increased risk of prostate cancer in younger men carrying known BRCA1
truncating mutations (relative to the general population), and the latter is consistent with our
previous report of a stronger linkage signal on chromosome 17q21 in families enriched for
prostate cancer(6). Together, these findings suggest that particular subsets of families,
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possibly those with more heritable forms of prostate cancer, contributed disproportionately
to our results. Of note, these strata defined only partially overlapping sets of families (i.e.,
less than 50% of informative families in one stratum were included in another stratum),
suggesting the presence of genetic heterogeneity.
Several groups have previously examined the role of BRCA1 Gln356Arg in cancer
susceptibility. For example, some(23;24) but not all groups(25–27) have reported an
association between Gln356Arg and breast cancer in case-control studies, with the Arg356
allele conferring a reduction in breast cancer risk. At least three other groups(28–30) have
also examined the role of BRCA1 Gln356Arg in case-control studies of ovarian cancer but
found no evidence of an association. To our knowledge, no case-control study has been
conducted to evaluate the role of BRCA1 Gln356Arg in prostate cancer, although Sinclair et
al.(11) and we(8) previously identified BRCA1 Gln356Arg in two small-scale studies of
high-risk prostate cancer families. Specifically, Sinclair et al.(11) found the Arg356 allele in
1 of 22 families after screening 43 individuals from families with at least three cases of
prostate cancer and at least two cases of breast and/or ovarian cancer. Similarly, after
screening for rare BRCA1 mutations in 93 unrelated men with prostate cancer from families
with a strong history of the disease and evidence of linkage to chromosome 17q21, we
initially reported only 1 family carrying the Arg356 allele(8) but subsequently confirmed
that Arg356 was also present in 13 other families. Notably, we did not identify any known
deleterious mutations in these 14 families, making it unlikely that they carry an obvious
loss-of-function mutation (e.g., a protein truncating mutation) in BRCA1.
Analysis of the HapMap samples suggests that the Arg356 allele is absent in samples of
African and Asian ancestry. Still, we observed 2 heterozygous men with prostate cancer in 1
of our 13 African American families (data not shown). In an independent case-control
sample of unrelated African American men with (n=128) and without (n=342) prostate
cancer from the Flint Men’s Health Study (FMHS)(31), we also identified 7 case (5.5%) and
5 control (1.5%) carriers. These data are consistent with European admixture in the African
American population. They also suggest that African American men carrying the Arg356
allele are more likely to develop prostate cancer than non-carriers, similar to their European
counterparts (based on the FMHS sample, age-adjusted OR = 4.17; 95% CI = 1.27–13.72;
p=0.02). Of note, a previous analysis of population substructure in the FMHS sample did not
reveal any significant differences in European ancestry between cases and controls(32),
suggesting that genetic admixture is unlikely to generate false positive evidence for
association.
Data from the FMHS add to the initial evidence from this study that genetic variation in the
BRCA1 gene is associated with prostate cancer. Still, we acknowledge several study
limitations. First, because our study included only a small number of families of African and
Asian ancestry, we were unable to evaluate the role of BRCA1 Gln356Arg in prostate cancer
susceptibility in these populations in the context of a family-based association design.
Second, the absence of the Arg356 allele in HapMap samples of non-European descent
suggests that the practical implications of our findings may be limited to specific
populations. Third, our findings may not generalize to sporadic and/or late-onset prostate
cancer since men in our study were ascertained from families with early-onset or familial
prostate cancer. In fact, preliminary data (October 10, 2006 release) from the Cancer
Genetic Markers of Susceptibility (CGEMS) project (a whole genome association study of
prostate cancer in men from the Prostate, Lung, Colorectal, and Ovary study) suggests that
the BRCA1 intronic SNPs that we tested, rs3737559 and rs799923, are not associated with
sporadic prostate cancer. It is worth noting, however, that SNP rs1799950 (BRCA1
Gln356Arg) has not been examined in the CGEM project.
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BRCA1 Gln356Arg is located in a region of exon 11 that binds Rad50 (which is part of the
DNA damage repair complex) and the transcriptional repressor ZBRK1. Some(33;34) but
not all(35) computational tools predict that the Gln356Arg substitution adversely affects
BRCA1 protein function. These tools compare orthologous sequences to establish whether
mutations occur in regions that are evolutionarily conserved and/or are evolving under
selective pressure. Alignment of exon 11 BRCA1 sequences for 57 placental mammals
indicates ~81% amino acid identity for the Gln allele at Gln356Arg (37). At present,
however, there are insufficient experimental data available to evaluate the functional
consequence, if any, of BRCA1 Gln356Arg.
It is important to note that we chose BRCA1 Gln356Arg not because of any prior knowledge
of potential function but because it tags a common haplotype. Thus, it is possible that the
associations observed in our study are due to LD with adjacent loci. In fact, it has been
previously documented that the BRCA1 gene falls within a 200–400 kb region of
chromosome 17q21 with suppressed recombination and strong LD(36;37). However, based
on the HapMap CEU sample (January 2006 release), Gln356Arg does not show evidence of
strong LD (R2≥ 0.5) with any known SNP on chromosome 17. Additionally, sequence
analysis of the 93 unrelated men with prostate cancer from our previous screening study(8)
indicates that Gln356Arg is not in LD (R2<0.07) with any coding SNP in the BRCA1 gene
(data not shown). Our other two associated SNPs, rs3737559 and rs799923, are located in
non-coding sequences with no obvious functional effect, and based on the HapMap CEU
sample, have a pair-wise R2 ≥ 0.5 with only 3 and 11 other known SNPs, respectively, on
chromosome 17, none of which are located in coding or known regulatory regions.
In summary, our findings support the hypothesis that common variation in the BRCA1 gene
plays a role in prostate cancer susceptibility. Several lines of evidence suggest that BRCA1
Gln356Arg, in particular, may influence prostate cancer-susceptibility. These include:
prostate cancer linkage to the BRCA1 region on chromosome 17q21 in two samples with
limited overlap; significant prostate cancer association with the Gln356Arg substitution;
evidence that Gln356Arg partially accounts for prostate cancer linkage to chromosome
17q21; and the absence of strong LD between Gln356Arg and any known SNP. Our results
suggest that future studies of familial cancer risk should include careful consideration of
common polymorphisms in genes implicated in hereditary cancer syndromes.
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Haplotype tag SNPs (htSNPs) and pair-wise linkage disequilibrium (LD) as measured by R2
in a 200 kb-region surrounding (and including) the BRCA1 gene. Blocks represent
consecutive sets of SNPs for which common haplotypes (with a frequency of at least 3%)
accounted for at least 80% of all predicted haplotypes. Two SNPs in the first block,
rs2271539 and rs691144, and four SNPs in the second block, rs1799966, rs3737559,
rs1799950, and rs799923, distinguished 94% and 96%, respectively, of haplotypes inferred
within the first and second blocks. SNP rs7223952, which is not present in the HapMap
database, is not an htSNP but is located in the second block and was in high LD with htSNP
rs1799966 (R2=0.94). Data are based on 323 unrelated, unaffected non-Hispanic white men
from our family-based association study.
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Non-parametric multipoint linkage analysis for prostate cancer on chromosome 17. Results
are based on the exponential model, the ‘pairs’ scoring statistic, and equal weights for each
of the families. The solid curve represents the maximum LOD (logarithm of the odds) score
for 154 of the 157 non-Hispanic white families previously published by Lange et al(6). The
dashed (dotted) curve represents the maximum LOD score for the 129 (25) families in which
no affected men (at least one affected man) carried one or more copies of the Arg356 allele
at BRCA Gln356Arg (or equivalently, SNP rs1799950).
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